在癌症和癌症治疗中,神经质衍生抑制细胞的可塑性
Jiajia Lv1, Xiaoyou Zhong1, Lin Wang1
1Department of Hematology and Oncology, Geriatric Hospital of Nanjing Medical University, Jiangsu Province Geriatric Hospital, Nanjing, 210000, China.
Oncology research
|July 4, 2025
概括
骨髓系衍生抑制细胞 (MDSCs) 是瘤免疫逃避的关键. 它们的可塑性使它们能够在瘤微环境中适应,影响癌症的进展和组合治疗的有效性.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
背景情况:
- 瘤微环境 (TME) 是一个支持瘤生长的复杂系统.
- 骨髓衍生抑制细胞 (MDSCs) 是TME中的关键免疫抑制成分.
- MDSCs阻碍抗瘤免疫反应,并促进瘤的进展.
研究的目的:
- 在TME中审查MDSC的可塑性.
- 阐明MDSC介导免疫调节背后的机制.
- 探索MDSC可塑性在癌症治疗中的治疗影响.
主要方法:
- 文献综述侧重于MDSC在TME中的可塑性和功能.
- 分析MDSCs抑制免疫反应的机制.
- 检查MDSC可塑性在癌症治疗有效性中的作用.
主要成果:
- MDSCs表现出显著的可塑性,分化成各种髓状细胞.
- 这种可塑性有助于它们在TME中的异质性和适应性.
- MDSC的可塑性影响了TME的整体免疫抑制性质.
结论:
- 了解MDSC可塑性对于理解瘤免疫逃避至关重要.
- 针对MDSC可塑性提供了增强癌症免疫治疗的潜在策略.
- MDSC可塑性在组合癌症治疗的成功中起着至关重要的作用.
相关概念视频
Differentiation of Common Myeloid Progenitor Cells
3.3K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.3K
Cancer Stem Cells and Tumor Maintenance
5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
Mesenchymal Stem Cells
5.0K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
5.0K
Regulation of Hematopoietic Stem Cells
3.3K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.3K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


